Yoh, Kiyotaka http://orcid.org/0000-0001-6928-357X
Hirashima, Tomonori
Saka, Hideo
Kurata, Takayasu
Ohe, Yuichiro
Hida, Toyoaki
Mellemgaard, Anders
Verheijen, Remy B.
Ou, Xiaoling
Ahmed, Ghada F.
Hayama, Manabu
Sugibayashi, Ko
Oxnard, Geoffrey R.
Funding for this research was provided by:
AstraZeneca
Article History
Accepted: 2 March 2021
First Online: 3 May 2021
Declarations
:
: The study (NCT02143466) was funded by AstraZeneca (Cambridge, UK), the manufacturers of savolitinib and osimertinib.
: KY received honoraria and research funds from AstraZeneca. TH received honoraria from Ono, Eli Lilly, AstraZeneca, Taiho, Chugai, MSD and Boehringer Ingelheim; research funds from Ono, Eli Lilly, AstraZeneca, Taiho, Chugai, Merck Serono, MSD and Boehringer Ingelheim. HS received honoraria from AstraZeneca and research funds from MSD, AstraZeneca, BMS, Takeda, Ono and Parexel. TK received honoraria from AstraZeneca, Eli Lilly, MSD, Ono, Boehringer Ingelheim, Chugai and Bristol Myers; research funds from Bristol Myers, Takeda, MSD, AstraZeneca and Novartis. YO received honoraria from AstraZeneca and Chugai; research funds from AstraZeneca, Chugai, ONO, BMS, Kyorin, Dainippon- Sumitomo, Taiho, Kissei, Ignyta, Takeda, Janssen and LOXO. TH received honoraria and research funds from AstraZeneca and Novartis. AM reports employment for AstraZeneca. RBV reports former employment for AstraZeneca and current employment for Johnson & Johnson; holding shares of AstraZeneca, Aduro Biotech and Johnson & Johnson. GFA reports former employment for AstraZeneca and current employment for UCB Pharma Ltd. MH, XO, KS report employment for AstraZeneca. GO reports employment for Foundation Medicine and honoraria from AstraZeneca.
: The study was conducted in accordance with the Declaration of Helsinki Good Clinical Practice guidelines (as defined by the International Conference on Harmonisation), applicable regulatory requirements, the Good Clinical Practice for Trials on Drugs’ (Japanese Ministry of Health, Labour, and Welfare Ordinance No. 28, 27 March 1997), and the policy on bioethics and human biological samples of the trial sponsor, AstraZeneca.
: Patients provided written informed consent.
: Data underlying the findings described in this article may be obtained in accordance with AstraZeneca’s data sharing policy described at ExternalRef removed.
: Conception and design: Ghada Ahmed, Anders Mellemgaard, Geoffrey Oxnard. Collection and assembly of data: Kiyotaka Yoh, Tomonori Hirashima, Hideo Saka, Takayasu Kurata, Yuichiro Ohe, Toyoaki Hida, Anders Mellemgaard, Remy Verheijen. Data analysis and interpretation: All authors. Drafting the manuscript: All authors. Manuscript writing: No authors, see medical writing acknowledgement. All authors read and approved the final draft of the manuscript. All authors agree to be accountable for all aspects of the work, which includes ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.